Sell Trimeris Down to 50 Cents – Analyst Blog
Source: http://www.zacks.com/stock/news/17016/Sell+Trimeris+Down+to+50+Cents+-+Analyst+BlogPosted on Tuesday, January 27th, 2009 | In Stocks to Watch
Trimeris, Inc. (TRMS) develops therapeutic agents for the treatment of viral diseases based on its fusion inhibition technology that blocks viral entry into host cells. Sales of its lead drug Fuzeon has been declining dramatically since 1Q08 due to fierce competition from Selzentry and Isentress.
The collaboration amendment with Roche and several management changes further cast a shadow on the company’s future. We maintain our Sell rating on Trimeris with a $0.50 price target.
At this point, it’s very difficult to value the stock. We believe qualitative factors prevail currently. There are many uncertainties about Trimeris due to the management change and collaboration amendment with Roche. The company is profitable but will find it tough to stay so if Fuzeon sales continue their downward slide.
Read the full analyst report on TRMS
“TRMS” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Settlement in Xerox-ACS Merger - Analyst Blog - November 24th, 2009
- Citi Expects Strong Economic Growth - Analyst Blog - November 24th, 2009
- Downgrading Expedia to Neutral - Analyst Blog - November 24th, 2009
- Foot Locker Misses Expectations - Analyst Blog - November 24th, 2009
- Patni Exceeds Estimates - Analyst Blog - November 24th, 2009
Blog, cent;, fusion inhibition ;, fusion inhibition technology;, Fuzeon, Stocks to Watch, therapeutic agents;, treatment of viral diseases;, Trimeris Inc., USD, viral diseases;, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.